drugset
drugset / Trial / NCT04144049

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

NCT04144049 ↗

Phase 2 Completed 176 enrolled Medy-Tox
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled, dose-ranging, parallel, multi-center, phase II study to evaluate the efficacy and safety of MT921 in subjects with moderate to severe submental fat.

Timeline

Start
2019-09-10
Primary completion
2020-03-10
Completion
2020-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject MT921 Unknown 0.2 ml Subcutaneous
Subject MT921 Unknown 1 % Subcutaneous
Subject MT921 Unknown 1.5 % Subcutaneous

Indications

No indication recorded.